Michael H. Schild
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Michael H. Schild has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
Thomas J. Cummings
Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA
4 shared publicationsCarlos E. Vargas
2 shared publicationsGary A. Ezzell
2 shared publicationsMichael C. Roarke
2 shared publicationsSameer R. Keole
2 shared publicationsSujay A. Vora
2 shared publications
Latest Publications
- Open Access
- 8 January 2020
- Published by BMJ in BMJ Case Reports
- Vol. 13 (1) , e233530
Incidental urothelial rest within the vermiform appendix of a paediatric male patient: an extremely rare entity
- 8 January 2020
- Published by BMJ in BMJ Case Reports
- Vol. 13 (1) , e233530
Open AccessIncidental urothelial rest within the vermiform appendix of a paediatric male patient: an extremely rare entity
- Open Access
- 1 June 2018
- Published by Wolters Kluwer Health in Medicine
- Vol. 97 (26) , e11271
Primary central nervous system histiocytic sarcoma
Primary central nervous system histiocytic sarcoma (PCNSHS) is a rare lymphohematopoietic tumor with a histiocytic cell origin. To our knowledge, only 28 cases have been published in English and 2 cases in Chinese. A 49-year-old Asian female presented to the hospital with a 2 month history of hypomnesia, odynophagia, and gait disorder. Physical examination demonstrated decreased lower extremity muscle strength. The patient denied a history of malignancy. Radiology demonstrated a lesion in parietal lobe with uniformenhancement. Histologic analysis showed pleomorphic tumor cells with a loose arrangement, effacing the normal brain tissue. The tumor cells exhibited abundant eosinophilic cytoplasm, highly atypical nuclei and predominant nucleoli. Immunohistochemistry revealed positive immunoreactivity for CD45, lysozyme, CD68, and CD163, and negative for pan-cytokeratin (CK), epithelial membrane antigen (EMA), glial fibrillary acidic protein (GFAP), CD3, CD20, CD1a, CD79a, CD138, oligodendrocyte transcription factor (olig2), CD15, melan-A, CD30, CD21, CD35, Human Melanoma Black-45 (HMB45), and anaplastic lymphoma kinase-1 (ALK-1). The diagnosis of PCNSHS was rendered. The patient underwent complete surgical resection and adjuvant radiotherapy. Follow-up information shows the patient died 8 months following the initial diagnosis. PCNSHS is extremely rare with an aggressive clinical course. Immunohistiochemistry is necessary to make this diagnosis and to exclude other primary intracranial and lymphohematopoietic tumors. Further research is required to improve the outcome of patients with PCNSHS.
- 1 June 2018
- Published by Wolters Kluwer Health in Medicine
- Vol. 97 (26) , e11271
Open AccessPrimary central nervous system histiocytic sarcoma
Primary central nervous system histiocytic sarcoma (PCNSHS) is a rare lymphohematopoietic tumor with a histiocytic cell origin. To our knowledge, only 28 cases have been published in English and 2 cases in Chinese. A 49-year-old Asian female presented to the hospital with a 2 month history of hypomnesia, odynophagia, and gait disorder. Physical examination demonstrated decreased lower extremity muscle strength. The patient denied a history of malignancy. Radiology demonstrated a lesion in parietal lobe with uniformenhancement. Histologic analysis showed pleomorphic tumor cells with a loose arrangement, effacing the normal brain tissue. The tumor cells exhibited abundant eosinophilic cytoplasm, highly atypical nuclei and predominant nucleoli. Immunohistochemistry revealed positive immunoreactivity for CD45, lysozyme, CD68, and CD163, and negative for pan-cytokeratin (CK), epithelial membrane antigen (EMA), glial fibrillary acidic protein (GFAP), CD3, CD20, CD1a, CD79a, CD138, oligodendrocyte transcription factor (olig2), CD15, melan-A, CD30, CD21, CD35, Human Melanoma Black-45 (HMB45), and anaplastic lymphoma kinase-1 (ALK-1). The diagnosis of PCNSHS was rendered. The patient underwent complete surgical resection and adjuvant radiotherapy. Follow-up information shows the patient died 8 months following the initial diagnosis. PCNSHS is extremely rare with an aggressive clinical course. Immunohistiochemistry is necessary to make this diagnosis and to exclude other primary intracranial and lymphohematopoietic tumors. Further research is required to improve the outcome of patients with PCNSHS.
- 1 June 2018
- Published by Elsevier in Surgical Pathology Clinics
- Vol. 11 (2) , 267-285
Nonalcoholic Steatohepatitis
- 1 June 2018
- Published by Elsevier in Surgical Pathology Clinics
- Vol. 11 (2) , 267-285
Nonalcoholic Steatohepatitis
- 1 March 2018
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Neuropathology
- Vol. 37 (03) , 85-86
Primary intracranial leiomyoma in an immunocompetent patient
- 1 March 2018
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Neuropathology
- Vol. 37 (03) , 85-86
Primary intracranial leiomyoma in an immunocompetent patient
- 1 November 2017
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Neuropathology
- Vol. 36 (6) , 291-292
Olfactory ensheathing cell tumor: a case presentation
- 1 November 2017
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Neuropathology
- Vol. 36 (6) , 291-292
Olfactory ensheathing cell tumor: a case presentation
- 1 September 2017
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 141 (9) , e2-e191
Abstracts and Case Studies From the College of American Pathologists 2017 Annual Meeting (CAP17)
Article Citation: (2017) Abstracts and Case Studies From the College of American Pathologists 2017 Annual Meeting (CAP17). Archives of Pathology & Laboratory Medicine: September 2017, Vol. 141, No. 9, pp. e2-e191. https://doi.org/10.5858/arpa.2017-0238-AB
- 1 September 2017
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 141 (9) , e2-e191
Abstracts and Case Studies From the College of American Pathologists 2017 Annual Meeting (CAP17)
Article Citation: (2017) Abstracts and Case Studies From the College of American Pathologists 2017 Annual Meeting (CAP17). Archives of Pathology & Laboratory Medicine: September 2017, Vol. 141, No. 9, pp. e2-e191. https://doi.org/10.5858/arpa.2017-0238-AB
- 1 September 2017
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Neuropathology
- Vol. 36 (09) , 248-249
Mixed hemangioblastoma and ependymoma collision tumor of the cerebellum
- 1 September 2017
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Neuropathology
- Vol. 36 (09) , 248-249
Mixed hemangioblastoma and ependymoma collision tumor of the cerebellum
- 1 June 2017
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 98 (2) , E6
(S018) A Prospective Trial of Intensity-Modulated Radiation Therapy (IMRT) Incorporating a Simultaneous Integrated Boost for Prostate Cancer: Long-Term Outcomes Compared With Standard Image-Guided IMRT
- 1 June 2017
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 98 (2) , E6
(S018) A Prospective Trial of Intensity-Modulated Radiation Therapy (IMRT) Incorporating a Simultaneous Integrated Boost for Prostate Cancer: Long-Term Outcomes Compared With Standard Image-Guided IMRT
- 1 April 2017
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 97 (5) , 1021-1025
A Prospective Trial of Intensity Modulated Radiation Therapy (IMRT) Incorporating a Simultaneous Integrated Boost for Prostate Cancer: Long-term Outcomes Compared With Standard Image Guided IMRT
- 1 April 2017
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 97 (5) , 1021-1025
A Prospective Trial of Intensity Modulated Radiation Therapy (IMRT) Incorporating a Simultaneous Integrated Boost for Prostate Cancer: Long-term Outcomes Compared With Standard Image Guided IMRT
- Open Access
- 1 March 2016
- Published by SAGE Publications in Rare Tumors
- Vol. 8 (1) , 17-19
Langerhan's Cell Sarcoma: Two Case Reports
Langerhan's cell sarcoma (LCS) is a rare neoplasm with a poor prognosis. To our knowledge, only sixty-six cases have been published. We discuss two patients who presented very differently with LCS, as well as a recently published review of all sixty-six cases. Our first case had a complicated history of metastatic, high-grade myxofibrosarcomas and presented with a single skin lesion of LCS which was treated with resection to a positive margin and adjuvant radiotherapy. The LCS recurred locoregionally and was again resected. The patient is alive two years after initial diagnosis. The second case presented with bone marrow and splenic involvement, leukocytosis, and thrombocytopenia. This patient had an excellent response to etoposide, prednisone, oncovorin, cyclophosphamide, and adriamycin, with normalization of the complete blood count, negative bone marrow biopsy at follow up, and splenectomy without viable neoplasm. This patient is alive without signs of disease at 16 months after initial diagnosis.
- 1 March 2016
- Published by SAGE Publications in Rare Tumors
- Vol. 8 (1) , 17-19
Open AccessLangerhan's Cell Sarcoma: Two Case Reports
Langerhan's cell sarcoma (LCS) is a rare neoplasm with a poor prognosis. To our knowledge, only sixty-six cases have been published. We discuss two patients who presented very differently with LCS, as well as a recently published review of all sixty-six cases. Our first case had a complicated history of metastatic, high-grade myxofibrosarcomas and presented with a single skin lesion of LCS which was treated with resection to a positive margin and adjuvant radiotherapy. The LCS recurred locoregionally and was again resected. The patient is alive two years after initial diagnosis. The second case presented with bone marrow and splenic involvement, leukocytosis, and thrombocytopenia. This patient had an excellent response to etoposide, prednisone, oncovorin, cyclophosphamide, and adriamycin, with normalization of the complete blood count, negative bone marrow biopsy at follow up, and splenectomy without viable neoplasm. This patient is alive without signs of disease at 16 months after initial diagnosis.